|
|
 |
Vexol
:This medication is used in the eye to reduce inflammation (redness
and swelling).
Side Effects:
This
medication may temporarily sting or burn your eyes when first applied.
If this continues or become bothersome or the condition for which
this was prescribed does not improve within several days, inform
your doctor.
Vision may be temporarily unstable for a few minutes after applying
this.
Use caution if driving or performing duties requiring clear vision.
Notify your doctor if you develop a skin rash, itching, eye pain
or redness or any other eye discomfort in or around the eyes or
a headache while using this medication.
Precautions:
Tell
your doctor if you have any eye problems, infections, cataracts
or allergies.
This medication should be used only if clearly needed during pregnancy
or while breast-feeding.
Discuss the risks and benefits with your doctor.
Generic Name: Rimexolone
Related:
Vexol 1% Suspension, Drop - Prescription
immunomodulators.pdf
ï Surodex (dexamethosone implant [Oculex]) ï
Envision TD (fluocinolone acetonide implant [B&L)] Immunomodulators
are potent modifiers of the inflammatory process.
Interferon in various forms is a potent immunomodulator which is
gradually finding many applications including the treatment of Hepatitis
C, Rheumatoid Arthritis, and Multiple Sclerosis.
A number of the listed medications are cyclo-oxygenase inhibitors
that inhibit the enzyme cyclo-oxygenase markedly reducing the synthesis
of prostaglandins.
Patanol is an inhibitor of the release of histamine from the mast
cells and it is a relatively, selective histamine H1 antagonist
that inhibits type 1 immediate hypersensitivity reaction.
Zaditor is a relatively selective, non-competitive histamine antagonist
(H1 receptors) and mast cell stabilizer.
Alamast, and Alocril are mast cell stabilizers.
The immunomodulators are valuable for the treatment of giant papillary
conjunctivitis and vernal conjunctivitis (Ocufen, Profenal, Feldene,
and Lotemax).
Several of the oral medications are valuable for the treatment of
cystoid macular edema (Oruvail, Toradal, and Indocin); Indocin ophthalmic
solution is also being investigated for the treatment of cystoid
macular edema.
The use of Acular and Voltaren and other immunomodulators in combination
with ocular steroids is becoming more common with photorefractive
keratectomy and their use has helped to reduce complications as
well as reducing the mild to moderate pain associated with corneal
procedures.
Vexol is a new "soft" steroidal immunomodulator ("soft"
medications have more rapid systemic metabolism and excretion via
decreased half-lives resulting in reduced side effects).
Vexol is approved for the treatment of anterior uveitis and for
post-operative inflammation control.
Loteprednol etabonate (Lotemax .5% and Alrex .2%) are "soft"
steroids, that are effective for uveitis and ocular allergies. mast
cell, Vexol.
bulletin40.pdf
The following amendments will take effect on September
15, 2003.
The amended Manitoba Specified Drug Regulation and Drug Interchangeability
Formulary Regulation will be available on the Manitoba Health website
http://www.gov.mb.ca/health/mdbif on the effective date of September
15, 2003.
*Abbreviation of Manufacturers' Names **Clozapine: After reviewing
the available evidence, the Manitoba Drug Standards and Therapeutics
Committee has agreed to designate the new Gen-Clozapine product
and the innovator product Clozaril as interchangeable.
Because of the well-known risk of agranulocytosis associated with
the use of clozapine, weekly or every two-week hematological testing
is necessary prior to dispensing of the next supply of medication.
As a result, distribution of clozapine is regulated through a monitoring
system with specific requirements set by Health Canada which involves
registration of the patient, physician and pharmacist.
In order to ensure a seamless process and facilitate the work of
physicians and pharmacists in switching their patients, Manitoba
Health will accommodate the brand name price for a grace period
of two (2) months.
The following products will be considered for Pharmacare reimbursement
upon an individual prescriber/patient request basis.
Please note that Pharmacare does not cover cyclosporine for the
prevention of graft rejection following transplantation.
Rapamune would be added to existing therapy.
00294322 Zyloprim allopurinol 300 mg Tablets 28.78 ** The price
change has resulted in a change to the lowest price in the category.
Denotes the price of the lowest generic product in the product category.
The following categories will be priced "per mL" (instead
of "per Dose").
Notice has been received from the manufacturer that the following
products have been discontinued.
They will be deleted with the next Formulary amendments. Tablets,
sodium.
Vexol_PI.pdf
VEXOL®1 % Ophthalmic Suspension is a sterile, multi-dose
topical ophthalmic suspension containing the corticosteroid, rimexolone.
CLINICAL PHARMACOLOGY: Corticosteroids suppress the inflammatory
response to a variety of inciting agents of a mechanical, chemical,
or immunological nature.
In a controlled 6-week study of steroid responsive subjects, the
time to raise intraocular pressure was similar for VEXOL®1
% Ophthalmic Suspension and 0.1 % fluorometholone given four times
daily.
After decreasing the dosing frequency to once every two hours while
awake during the second week of administration, mean serum concentrations
were approximately 100 pg/mL.
INDICATIONS AND USAGE: VEXOL®1% (rimexolone ophthalmic suspension)
is indicated for the treatment of postoperative inflammation following
ocular surgery and in the treatment of anterior uveitis.
CONTRAINDICATIONS: VEXOL®1% (rimexolone ophthalmic suspension)
is contraindicated in epithelial herpes simplex keratitis (dendritic
keratitis), vaccinia, varicella, and most other viral diseases of
the cornea and conjunctiva; mycobacterial infection of the eye;
fungal diseases of the eye; acute purulent untreated infections
which, like other diseases caused by microorganisms, may be masked
or enhanced by the presence of the steroid; and in those persons
with hypersensitivity to any component of the formulation.
Prolonged use may result in ocular hypertension /glaucoma, damage
to the optic nerve, defects in visual acuity and visual fields,
and posterior subcapsular cataract formation.
Prolonged use may also result in secondary ocular infections due
to suppression of host response.
In those diseases causing thinning of the cornea or sclera, perforation
has been known to occur with topical steroids.
If this product is used for 10 days or longer, intraocular pressure
should be monitored even though it may be difficult in children
and uncooperative patients (see WARNINGS).
Information for Patients: Do not touch dropper tip to any surface,
as this may contaminate the suspension. ophthalmic suspension, dose.
|
